Corbus Pharmaceuticals to Present New Abstracts Data
Corbus Pharmaceuticals announced it will present three new abstracts on its cystic fibrosis research at an upcoming medical conference.
Corbus Pharmaceuticals (NASDAQ:CRBP) announced it will present three new abstracts on its cystic fibrosis research at an upcoming medical conference.
As quoted in the press release:
James Chmiel, M.D., M.P.H., Professor of Pediatrics, Case Western Reserve University, Associate Director of the LeRoy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, and Principle Investigator of Corbus’ Phase 2 cystic fibrosis clinical study will give an oral presentation, “Recent Advances in Anti-inflammatory Treatment,” on Friday, November 3, 2017 at 11:35 AM. As part of his presentation, Dr. Chmiel will review some of the latest trials of CF therapies including both CFTR modulators and immunomodulatory therapy for CF. Dr. Chmiel will also discuss clinical data from Corbus’ Phase 2 study of anabasum for the treatment of CF and other developments in the field.